The benefits of statins for primary prevention of coronary heart disease stand the test of time.
Results published in 1995 from the West of Scotland Coronary Prevention Study (WOSCOPS), a randomized, double-blind, placebo-controlled clinical trial of pravastatin in middle-aged men without a history of MI, demonstrated a significant benefit after approximately 5 years of treatment (Journal Watch Cardiology Dec 1 1995). Now, the WOSCOPS investigators report outcomes over the subsequent 10 years.
About one third of the study subjects took statins during the post-trial period; the percentages were slightly higher in those who were originally randomized to pravastatin. During follow-up (mean, 13.2 years for cancer and 14.7 years for other outcomes), 18.8% of the participants originally assigned to pravastatin died, compared with 20.5% of tho…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association